BioSpace News Archive

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to deliver the best patient care, will host its latest State of the Science Summit™ on ovarian cancer Wednesday, May 15, from 5-9 p.m. at The Langham Huntington in Pasadena, California

Agiliti, Inc. (“Agiliti”) today announced the results of its previously announced cash tender offer to purchase all of its outstanding warrants (the “Offer”) for $0.95 per warrant, in cash, without interest,

PrediLife (Euronext Growth Paris: ALPRE), a company developing innovative solutions predicting the risk of diseases to facilitate personalized medicine, is announcing that it is partnering with the Institut Curie for the launch of the next-generation of MammoRisk®, a test predicting breast cancer risk that now incorporates a polygenic score based on a saliva sample.

Proteintech, the benchmark in antibodies and proteins, welcomes Deepa Shankar, PhD, as the head of global Research and Development (R&D).

Media representatives are advised that The Leukemia & Lymphoma Society of Canada and Max Parrot, professional snowboarder and Olympic silver medalist, diagnosed with Hodgkin lymphoma, will make an announcement at a press conference.

Nuvera Life Science Consulting is a consulting company dedicated to helping the world’s leading pharmaceutical and biotech companies deliver impactful patient and HCP support experiences for specialty and rare-disease therapies.

Continuing its mission to lower healthcare costs and improve patient safety, CAIPHI is introducing CyPHIprepare™ an innovative and efficient cloud-based self-assessment tool that can help healthcare providers reduce the cost of emergency preparedness and save up to 90 percent over the cost of hiring outside intermediaries.

A San Diego second grader and a Mount Shasta resident give thanks to donors who saved their lives at May 10 event

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock.

FogPharma announced the appointment of Howard Stern, M.D., Ph.D., as Chief Scientific Officer.